France vs Saudi Arabia: Access to anti-retroviral drugs, female
France
93.0%
in 2022
Saudi Arabia
91.0%
in 2024
France rank
22nd
Saudi Arabia rank
25th
Access to anti-retroviral drugs, female over time
- France
- Saudi Arabia
How they compare
France currently reports 93.0% against 91.0% in Saudi Arabia, a difference of 2.0%.
Across all 23 years both countries report, France has been ahead every year.
France ranks 22nd and Saudi Arabia ranks 25th of 141 countries.
France has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | France | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 81.2% | 24.3% | 56.9% | France |
| 2010s | 90.4% | 62.5% | 27.9% | France |
| 2020s | 91.7% | 79.3% | 12.3% | France |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, France or Saudi Arabia?
- France, at 93.0% against 91.0% in Saudi Arabia as of 2022.
- What is the difference in access to anti-retroviral drugs, female between France and Saudi Arabia?
- 2.0%, with France ahead.
- How many years of comparable data are there for France and Saudi Arabia?
- 23 years are reported by both, from 2000 to 2022.
- How do France and Saudi Arabia rank globally for access to anti-retroviral drugs, female?
- France ranks 22nd and Saudi Arabia ranks 25th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.